Home World News Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves... World News Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 30, 2026 179 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTRUM-006 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Cancer Rehabilitation Starts at Diagnosis: Part II July 13, 2021 Cancer Screening Guidelines Often Lack Information on Potential Harms, Study Finds November 23, 2022 High HPV Vaccination Coverage in England Associated with a Substantial Reduction... June 25, 2026 Breast Cancer Patients with Low Breast Density May Be More Likely... January 18, 2021 Load more HOT NEWS Only a Quarter of Phase III Studies Demonstrated Improved QoL in... Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia Happy 29th Birthday OncoLink!
